公开(公告)号：US20250034227A1

公开(公告)日：2025-01-30

申请号：US18785378

申请日：2024-07-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Timo MANZ ,  Nadine ASCHMONEIT ,  Maike JAWORSKI ,  Lena SCHMOHL ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Nora TREIBER

IPC: C07K14/725 ,  A61K38/00 ,  A61P35/00

Abstract: The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2-expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.

公开(公告)号：US20220313805A1

公开(公告)日：2022-10-06

申请号：US17687297

申请日：2022-03-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220193212A1

公开(公告)日：2022-06-23

申请号：US17687274

申请日：2022-03-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210228698A1

公开(公告)日：2021-07-29

申请号：US17229556

申请日：2021-04-13

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210032361A1

公开(公告)日：2021-02-04

申请号：US16943779

申请日：2020-07-30

Applicant: Immatics Biotechnologies GmbH

Inventor： Meike HUTT ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER ,  Martin HOFMANN ,  Gabriele PSZOLLA ,  Sara YOUSEF ,  Claudia WAGNER ,  Frank SCHWOEBEL ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K14/725 ,  A61P35/00

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20210002610A1

公开(公告)日：2021-01-07

申请号：US16893246

申请日：2020-06-04

Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

Inventor： Amir ALPERT ,  Dominik MAURER ,  Anastasiya SMITH ,  Claudia WAGNER ,  Ali MOHAMED

IPC: C12N5/0783 ,  A61K31/5383 ,  A61K31/437

Abstract: Described herein are methods for preparing T cells, including isolating CD8+ T cells from a blood sample obtained from a patient or a donor, culturing the isolated CD8+ T cells in the presence of at least one cytokine, contacting the cultured CD8+ T cells with a multimer containing a target peptide in a complex with an MHC molecule and with at least one binding agent that binds to a T cell surface molecule, in which the multimer is labelled with a first detectable agent and the binding agent is labelled with a second detectable agent, sorting the contacted CD8+ T cells to collect the sorted CD8+ T cells that are detected positive for the first and the second detectable agents, and expanding the collected CD8+ T cells.

公开(公告)号：US20200249233A1

公开(公告)日：2020-08-06

申请号：US16828577

申请日：2020-03-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

IPC: G01N33/574 ,  G01N33/58 ,  C07K16/28 ,  A61K39/395 ,  A61K35/17 ,  A61K39/00 ,  C07K16/30 ,  C07K14/725 ,  A61P35/00 ,  C07K14/705

Abstract: The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20200230222A1

公开(公告)日：2020-07-23

申请号：US16839412

申请日：2020-04-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/74 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190375809A1

公开(公告)日：2019-12-12

申请号：US16519959

申请日：2019-07-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: C07K14/47 ,  C07K14/725 ,  A61K35/17 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/74 ,  A61P35/00 ,  C07K16/30 ,  G16B20/20 ,  G01N33/574 ,  C12Q1/6886 ,  A61K39/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190256572A1

公开(公告)日：2019-08-22

申请号：US16403038

申请日：2019-05-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER ,  Mathias FERBER

IPC: C07K14/725 ,  C07K16/30

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.